




Attenuated CSF-1R signalling drives cerebrovascular pathology

Conor Delaney¹ , Michael Farrell², Colin P Doherty^{3,4,5}, Kiva Brennan⁶, Eoin O’Keeffe¹, Chris Greene¹, Kieva Byrne¹, Eoin Kelly³, Niamh Birmingham⁷, Paula Hickey⁸, Simon Cronin⁷, Savvas N Savvides^{9,10}, Sarah L Doyle⁶  & Matthew Campbell^{1,5,*} 

Abstract

Cerebrovascular pathologies occur in up to 80% of cases of Alzheimer’s disease; however, the underlying mechanisms that lead to perivascular pathology and accompanying blood–brain barrier (BBB) disruption are still not fully understood. We have identified previously unreported mutations in colony stimulating factor-1 receptor (*CSF-1R*) in an ultra-rare autosomal dominant condition termed adult-onset leucoencephalopathy with axonal spheroids and pigmented glia (ALSP). Cerebrovascular pathologies such as cerebral amyloid angiopathy (CAA) and perivascular p-Tau were some of the primary neuropathological features of this condition. We have identified two families with different dominant acting alleles with variants located in the kinase region of the *CSF-1R* gene, which confer a lack of kinase activity and signalling. The protein product of this gene acts as the receptor for 2 cognate ligands, namely colony stimulating factor-1 (CSF-1) and interleukin-34 (IL-34). Here, we show that depletion in *CSF-1R* signalling induces BBB disruption and decreases the phagocytic capacity of peripheral macrophages but not microglia. *CSF-1R* signalling appears to be critical for macrophage and microglial activation, and macrophage localisation to amyloid appears reduced following the induction of *Csf-1r* heterozygosity in macrophages. Finally, we show that endothelial/microglial cross-talk and concomitant attenuation of *CSF-1R* signalling causes remodelling of BBB-associated tight junctions and suggest that regulating BBB integrity and systemic macrophage recruitment to the brain may be therapeutically relevant in ALSP and other Alzheimer’s-like dementias.

Keywords adult-onset leucoencephalopathy with axonal spheroids and pigmented glia (ALSP); blood; brain barrier; CSF-1; CSF-1R; IL-34

Subject Categories Genetics, Gene Therapy & Genetic Disease; Neuroscience

DOI 10.15252/emmm.202012889 | Received 5 June 2020 | Revised 19 November 2020 | Accepted 23 November 2020 | Published online 22 December 2020

EMBO Mol Med (2021) 13: e12889

Introduction

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterised by a gradual decline in cognitive function and is the most common cause of dementia in the elderly. Currently, there are approximately 36 million people worldwide who suffer from AD and other dementias and there are no approved medicines to prevent disease progression. The central neuropathological hallmarks of AD are as follows: (i) the extracellular accumulation of amyloid- β (A β) in parenchymal plaques and (ii) the formation of intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated forms of the microtubule-associated protein tau. Additionally, up to 80% of AD patients display cerebrovascular pathologies such as cerebral amyloid angiopathy (CAA) as well as in over 30% of cases of non-Alzheimer’s dementia (Matthews *et al*, 2009). CAA is characterised by an accumulation of A β in the parenchymal space, within vessel walls of arteries (namely the cerebral, leptomeningeal and parenchymal arteries) or around small- to medium-sized blood vessels. The underlying mechanism that leads to A β accumulation in this perivascular pattern is still not fully understood. It is accepted, however, that CAA can contribute to dementia onset and cognitive decline through increasing susceptibility for microbleeds, cerebral ischaemia and chronic activation of pro-inflammatory mechanisms in the surrounding parenchyma (Kinnecom *et al*, 2007; Vukic *et al*, 2009).

Recently, we have examined post-mortem brain tissues from two families with an ultra-rare condition termed adult-onset

1 Smurfit Institute of Genetics, Trinity College Dublin, Dublin 2, Ireland
 2 Department of Neuropathology, Beaumont Hospital, Dublin 9, Ireland
 3 Department of Neurology, Health Care Centre, St James’s Hospital, Dublin 8, Ireland
 4 Academic Unit of Neurology, Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland
 5 FutureNeuro SFI Research Centre, Royal College of Surgeons in Ireland, Dublin, Ireland
 6 Trinity College Institute of Neuroscience, Trinity College Dublin 2, Dublin 2, Ireland
 7 Department of Medicine, University College Cork, Cork, Ireland
 8 Sligo Regional Hospital, Sligo, Ireland
 9 Unit for Structural Biology, Department of Biochemistry and Microbiology, Ghent University, Ghent, Belgium
 10 VIB-UGent Center for Inflammation Research, Ghent, Belgium
 *Corresponding author. Tel: +353 1 8961482; Fax: +353 1 8963848; Email: matthew.campbell@tcd.ie

leucoencephalopathy with axonal spheroids and pigmented glia (ALSP). Individuals in this family presented clinically with early-onset dementia (in their forties) that had been reported within the family previously. Indeed, many of the reported symptoms for ALSP are akin to those reported in AD, namely depression, cognitive impairment, gait disturbances, speech problems and overt neurodegeneration. Adult-onset leucoencephalopathies accompanied by spheroids and pigmented glia were initially categorised as two main conditions, hereditary diffuse leucoencephalopathy with axonal spheroids (HDLS) and familial pigmentary orthochromatic leucodystrophy (POLD). While these clinical conditions have been known for nearly 40 years as distinct entities (Van Bogaert, 1936; Axelsson *et al*, 1984), the genetic cause of the two were reported within the past 10 years as being associated with dominant acting mutations in the colony stimulating factor-1 receptor (*CSF-1R*) gene (Rademakers *et al*, 2011). Due to the shared genetic aetiology of the conditions (Nicholson *et al*, 2013), they are now considered to be part of the spectrum of the same disease, which has been termed ALSP (Adams *et al*, 2018).

CSF-1R is activated via common structural principles by two distinct cytokine ligands, namely colony stimulating factor-1 (CSF-1) and interleukin-34 (IL-34) (Elegheert *et al*, 2011; Ma *et al*, 2012; Felix *et al*, 2013, 2015) which are both essential for microglial viability, development and proliferation (Askew *et al*, 2017; Bohlen *et al*, 2017; Wu *et al*, 2018). CSF-1R is also critical for myeloid lineage cell differentiation, as well as that of peripheral monocytes into circulating and tissue-resident macrophages (Wang *et al*, 2012; Rojo *et al*, 2019), and was recently found to be mutated in gain-of-function pathologic variants in histiocytic neoplasms (Durham *et al*, 2019). While CSF-1R is expressed in some cells of the adult brain under homeostasis, namely microglia, it and its ligands have been shown to be upregulated and neuroprotective in mouse disease models of AD and epilepsy (Luo *et al*, 2013; Schwarzer *et al*, 2019). In addition to CSF-1R signalling appearing to be a critical pathway for responding to CNS insult, IL-34 is secreted by neuronal cells under normal conditions and can enhance neuroprotective effects of microglia in response to stimuli such as oligomeric amyloid (Schwarzer *et al*, 2019). While CSF-1R has been detected previously in mouse endothelial cells within the brain and spinal cord (Jin *et al*, 2014), and exhibits endothelial expression in human cortical tissue (Uhlén *et al*, 2015), it has still not been fully confirmed that brain endothelial cells actually express the protein. In this regard, the expression pattern of CSF1R in the brain endothelium has yet to be fully characterised.

As CSF-1R is essential for the survival of the vast majority of microglial populations, it has recently become a commonly targeted receptor in drug development programmes for epilepsy and AD. CSF-1R inhibition in pre-clinical models using small molecules such as PLX3397 and PLX5622 has been shown to be effective in depleting up to 99% of microglia within 3 weeks of administration in chow (Luo *et al*, 2013; Rice *et al*, 2015; Dagher *et al*, 2015; Renee *et al*, 2015; Spangenberg *et al*, 2016, 2019; Bohlen *et al*, 2017; Singh *et al*, 2017; Elmore *et al*, 2018; Srivastava *et al*, 2018). Many of these studies report beneficial outcomes in mouse models of AD including reduced plaque burden (Rice *et al*, 2015), neuroinflammation (Spangenberg *et al*, 2016) and improved cognition (Dagher *et al*, 2015). However, these microglia-ablation studies have also produced conflicting data related to whether microglial ablation affects the rate of

A β deposition and cognition improvement. Furthermore, cognitive improvement has not been sustained following repopulation of the brain by microglia in these models. Whether the beneficial effects of CSF-1R inhibition are due to ameliorating a key process in the development of AD in these mice, or transiently inhibiting the overall effects of microglial inflammatory processes on cognition, has not been established.

Here, we have observed A β -associated cerebrovascular pathology accompanied by BBB breakdown in 2 separate families with previously unreported and different dominant acting mutations in the kinase region of CSF-1R. These mutations lead to a profound loss of function of CSF-1R and attenuated signalling, rendering affected individuals essentially haploinsufficient for *CSF-1R*. Surprisingly however, we found that microglial cells heterozygous for *Csf-1r* retain robust phagocytic ability, but macrophages with depleted CSF-1R signalling are significantly compromised. We show that dysregulated CSF-1R-dependent endothelial/microglial cell crosstalk induces re-modelling of the BBB in mouse and human and suggests that regulating BBB integrity while promoting macrophage recruitment to the brain may be therapeutically viable in ALSP and other AD-like dementia. Added to this, autologous bone marrow transplants could show real and meaningful clinical readouts in ALSP patients.

Results

Dominant mutations in CSF-1R induce cerebral amyloid angiopathy (CAA) and cerebrovascular pathology

We identified 2 separate families showing clinical evidence of the ultra-rare condition ALSP. Concomitantly, we confirmed the presence of mutations within the kinase region of the *CSF-1R* gene, Δ A781_N783 in one family (Fig 1A) and a P824R mutation in another (Fig 1B). Post-mortem analysis of the brains of 3 genetically diagnosed ALSP cases revealed extensive cerebral atrophy (Figs 1C and D and EV1). Widespread white matter Wallerian degeneration was also observed (Fig 1E). Very extensive axonal spheroids were apparent when sections of brain tissue were stained for neurofilament (Fig 1F). Furthermore, widespread cerebral amyloid angiopathy (CAA), involving meningeal and intraparenchymal blood vessels, was also evident in tandem with severe arteriosclerosis in subcortical white matter (Fig 1G and H). An identical pathology was observed in all 3 post-mortem cases of ALSP. Perivascular accumulation of phosphorylated Tau (P-tau) (Fig 1I and J) and amyloid-beta (A β) was clearly evident, and observation of such unique pathologies in a single disease points towards a deficit in the underlying processes through which these proteins aggregate and/or are cleared across the endothelium that constitutes the BBB.

Mutations in CSF-1R attenuate kinase activity and signalling

ALSP is primarily inherited in an autosomal dominant manner, and in these particular families, it results from either a 9-base-pair in-frame deletion in the *CSF-1R* gene, (c.2342_2350del) leading to an Ala781-Arg782-Asn783 deletion, or a single point mutation (c.2741C > G) leading to a Pro824Arg substitution. These are




Figure 1. Identification of familial variants in *CSF-1R*.

- A, B Family pedigrees for *CSF-1R* variants $\Delta A781_N783$ and P824R, with Sanger sequencing confirmations for each variant below.
 C Cystic encephalomalacia evident in the right inferior frontal lobe secondary to a historical intraparenchymal haemorrhage.
 D Extensive atrophy evident in frontal lobe.
 E Secondary de-myelination observed with Luxol-Fast Blue stain.
 F Wallerian degeneration observed with spheroids apparent following phosphorylated neurofilament staining.
 G, H Profound cerebral amyloid angiopathy (CAA), involving meningeal and intraparenchymal blood vessels.
 I, J Extensive phospho-tau staining displaying a perivascular pattern of deposition.

previously unreported mutations in *CSF-1R* and based on sequence considerations both mutations would be expected to be found in the intracellular kinase domain of *CSF-1R*. Analysis of the structural context of these mutations using the crystal structure of the kinase domain of human *CSF-1R* (pdb entry 2OGV) (Walter *et al*, 2007) reveals that the mutated sites localise within highly conserved sequence cassettes in the C-lobe of the kinase region of *CSF-1R* (Fig 2A). In the case of the Ala781-Asn783 deletion mutation, the 3 amino acids are critical for comprising a unique left-handed helical secondary structural element within the active site of *CSF-1R* (Fig 2A). This allows projection of Arg782 to interact with the catalytic

residue Asp778 and the activation loop of *CSF-1R*. Furthermore, Ala781 makes key interactions with a hydrophobic core of the C-lobe (Fig 2A). Therefore, the Ala781-Asn783 deletion mutation would be predicted to be a loss-of-function mutation and to exhibit compromised protein stability. Similarly, Pro824 is found at the end of the activation loop of *CSF-1R* and nestles into a strictly hydrophobic pocket to provide structural anchoring and stability. Thus, a Pro824Arg mutation would be expected to be overwhelmingly incompatible with such an environment leading to destabilisation of both the activation loop of *CSF-1R* and part of the hydrophobic core of the C-lobe of the *CSF-1R* kinase domain (Fig 2A).




Figure 2.

Figure 2. The $\Delta A781_N783$ and P824R variants in CSF-1R are loss of function and have conserved cellular processing.

- A Structure–sequence analysis and context of the CSF-1R $\Delta A781_N783$ and P824R variants. Sequences used in the alignment correspond to Uniprot sequences for CSF-1R as follows: Human P07333, Cynomolgus Monkey A0A2K5WG91, Mouse P09581, Bovine A72067, Cat P13369, Zebrafish Q918N6.
- B Western blot for CSF-1R and Actin in HEK293 cells transfected with native and variant CSF-1R as indicated.
- C Densitometry (top) and qPCR analysis of native and variant CSF-1R expression in HEK293 cells relative to native-transfected at 24 and 48 h (**** $P < 0.0001$, **** $P < 0.0005$, ** $P < 0.005$ one-way ANOVA with Sidak's post-test for multiple comparison, $n = 3$ biological replicates, error bars indicate SEM).
- D–G Western blot for phosphorylated and total ERK in HEK293 cells transfected with native and $\Delta A781_N783$ (left) or P824R (right) CSF-1R and treated with CSF-1 (D, E) or IL-34 (F, G) for 10 min. Horizontal line indicates untreated cells, with increasing concentrations 10, 50 and 100 ng/ml. Corresponding densitometry displays the ratio of phospho-ERK to total ERK, normalised to the ratio of the untreated control for the native receptor (**** $P < 0.0001$, **** $P < 0.0005$, ** $P < 0.01$, * $P < 0.05$, one-way ANOVA with Sidak's post-test for multiple comparison, $n = 3$ biological replicates, error bars indicate SEM).
- H Western blot for CSF-1R in HEK293 cells transfected with native and $\Delta A781_N783$ (top) or P824R (bottom) CSF-1R and treated with rapamycin. Horizontal line indicates untreated cells, with concentrations 0.1, 0.5, 1, 5, 10 μM . Corresponding densitometry (below) displays the fold change of CSF-1R relative to the untreated control for each transfection (**** $P < 0.0001$, one-way ANOVA with Sidak's post-test for multiple comparison to untreated, $n = 3$ biological replicates, error bars indicate SEM).
- I Western blot for CSF-1R in HEK293 cells transfected with native and $\Delta A781_N783$ (top) or P824R (bottom) CSF-1R and treated with 3-methyladenosine. Horizontal line indicates untreated cells, with increasing concentrations 0.1, 0.2, 0.5, 1 mM. Corresponding densitometry (below) displays the fold change of CSF-1R relative to the untreated control for each transfection (**** $P < 0.0001$, * $P = 0.0114$, one-way ANOVA with Sidak's post-test for multiple comparison to untreated, $n = 3$ biological replicates, error bars indicate SEM).
- J Western blot for CSF-1R and Actin in HEK293 cells transfected with native and $\Delta A781_N783$ (top) or P824R (bottom) CSF-1R and treated with MG132 or PLX3397. Horizontal line indicates untreated cells, 20 μM PLX3397, with increasing concentrations 0.1, 0.5, 0.1, 5 μM . Corresponding densitometry (below) displays the fold change of CSF-1R relative to the untreated control for each transfection (**** $P = 0.0002$, ** $P = 0.002$, one-way ANOVA with Sidak's post-test for multiple comparison to untreated, $n = 3$ biological replicates, error bars indicate SEM).

Generation of a native CSF-1R gene in tandem with genes containing the 2 mutations clearly showed that protein expression levels of CSF-1R were decreased in both mutations, with no accompanying decrease in transcriptional activity (Fig 2B and C). Localisation of CSF-1R is still conserved to the plasma membrane even in the presence of a CSF-1R mutation, suggestive of no dominant-negative effect of the mutation (Fig EV2). The concept of mutant CSF-1R aggregating and accumulating in cells was then explored using a cell stress array approach. In cells over-expressing CSF-1R with the P824R variant, out of 84 cell stress-related genes examined only *DDIT3* and *CXCL8* had significantly altered gene expression values when compared to cells expressing native CSF-1R (Appendix Fig S1).

Importantly however, while stimulation of cells expressing native CSF-1R with recombinant CSF-1 (Fig 2D and E) or IL-34 (Fig 2F and G) at increasing doses caused increased and dose-dependent ERK phosphorylation, no ERK phosphorylation was evident in cells expressing mutant CSF-1R. p-ERK was observed in cells co-expressing native and mutant CSF-1R, suggestive of retained function of native CSF-1R in the presence of variant CSF-1R. The IL-34-mediated increase in p-ERK was reduced in the heterozygous context; however, in response to CSF-1, similar levels of ERK phosphorylation were observed in native-only and native-variant transfected cells. In order to rule out the possibility that absence of CSF-1R signalling is due to the reduced level of variant CSF-1R, we pre-treated cells with MG132 which can upregulate variant CSF-1R. No signalling was observed post-stimulation, confirming loss of function of CSF-1R signalling in both mutations (Fig EV3).

In order to ascertain a putative mechanism underlying the control of CSF-1R production and turnover, we examined the expression of native or mutant CSF-1R in the presence of increasing doses of an autophagy inducer (rapamycin) (Fig 2H), an autophagy inhibitor (3-methyladenosine) (Fig 2I) or a proteasomal inhibitor (MG132) (Fig 2J). Intriguingly, during autophagy inhibition, CSF-1R protein levels are increased independent of genotype. While autophagy induction also showed a dose-dependent increase in CSF-1R levels, inhibition of the proteasome appeared to specifically regulate levels of mutated CSF-1R and not native protein (Fig 2J).

Mutant and non-functioning CSF-1R protein decreases the phagocytic capacity of peripheral macrophages but not microglia

While CSF-1R is expressed in endothelial cells, the predominant cell types expressing this protein are immune cells of the myeloid lineage and microglia. Post-mortem analysis of ALSP patient brains showed a perivascular accumulation of CD68- and CD163-positive cells suggestive of peripheral macrophage involvement. To this end and in order to ascertain the effect of mutated CSF-1R on immune cell differentiation, we isolated PBMCs from an individual diagnosed with the $\Delta A781_N783$ CSF-1R mutation and compared them to a normal healthy donor. Interestingly, there was a very clear depletion of T cells, CD14⁺ macrophages in addition to B cells. Added to this, PBMCs from the ALSP patient also showed up to 90% lineage-negative cells (CD3/14/16/19/20/56) compared to a non-diseased sample (Fig 3A and B). It was also very clear that macrophages isolated from patients expressing either CSF-1R mutation displayed highly dysmorphic cells (Fig 3C). These cells accounted for 30% of all differentiated macrophages and had a significantly decreased phagocytic ability compared to macrophages isolated from healthy donors (Fig 3D–F). As CSF-1R is predominantly expressed in microglial cells in the adult mouse and human brain, we sought to determine whether the phagocytic ability of microglial cells was compromised in mice expressing only a single *Csf-1r* allele in microglia.

Unexpectedly, there was no difference between the phagocytic capacity of microglia with reduced CSF-1R signalling. Similarly, microglia which underwent pharmacological *Csf-1r* downregulation using siRNA had no change in the rate of phagocytosis (Fig 3G and H), and this was further confirmed through genetic *Csf-1r* reduction in mice. Primary microglia isolated from WT or microglial/macrophage-specific *Csf-1r*^{+/-} mice displayed no altered phagocytic capacity (Fig 3J–I), together suggesting that *Csf-1r* heterozygosity was dispensable for microglial phagocytosis. However, when we examined bone-marrow-derived macrophages (BMDM's) from the same animals, the phagocytic ability of *Csf-1r*^{+/-} BMDMs was significantly compromised similar to the human PBMCs, indicating a deficit in peripheral macrophage phagocytosis as opposed to

microglial cells (Fig 3L and M). These data suggest that in the human condition with *Csf1r* haploinsufficiency, activated microglia are still robustly phagocytically active, while it is peripheral macrophages that are compromised.

CSF-1R loss affects macrophage/microglial activation and brain recruitment

In order to ascertain whether endothelial or macrophage CSF-1R is central to immune cell response to a stimulus such as amyloid aggregation and clearance across the BBB, we injected amyloid-beta 1-42 unilaterally into the hippocampus of mice lacking a single *Csf1r* allele in microglial/macrophage cells (Fig 4A) or endothelial cells (Fig 4C). Reduced immune cell infiltration and activation (F4/80 positivity) was only evident in the context of macrophage (Fig 4B) *Csf1r* loss as opposed to endothelial cells (Fig 4D). This is of particular note in the context of CAA as the patrolling subset of monocytes in mice known to associate with the cerebral vasculature ($Ly6C^{lo}$, $Cx3CR1^{high}$, $CCR2^{-}$) develop in a CSF-1R-dependent manner (Yona et al, 2013). Targeted depletion of these

vessel-associated macrophages has previously been shown to induce an increase in A β load in the brain parenchyma as well as around the CNS vasculature (Michaud et al, 2013). Additionally, stimulation of these cells was also able to specifically reduce CAA load, highlighting the critical role of peripheral CSF-1R-dependent macrophage activity in driving amyloid clearance at the BBB (Hawkes & McLaurin, 2009).

Endothelial/microglial crosstalk induces tight junction re-modelling and BBB disruption in ALS

As mutations in *CSF-1R* and a lack of CSF-1R signalling can clearly induce cerebrovascular pathology in humans, we sought to elucidate the cell type responsible for mediating this phenotype. In that regard, we treated mouse microglial cells with two concentrations of the CSF-1R inhibitor PLX3397 (Hi, Lo) to observe the indirect effects of CSF-1R-inhibited microglia conditioned media (Hi-BVCM, Lo-BVCM) on endothelial cells (Fig 5A). Strikingly, we observed that cell culture media conditioned by microglia in the absence of PLX3397 could upregulate endothelial CSF-1R within 24 h of




Figure 3.

Figure 3. Peripheral variant CSF-1R macrophages have altered identity and function.

- A, B FACS of control and $\Delta A781_N783$ PBMCs using lineage markers for CD3 (T cells), CD14 (monocytes/macrophages), CD19 (B cells), CD16, CD20 and CD56. Cells negative for all 6 markers were determined to be lineage-negative (Lin⁻).
- C Immunocytochemistry of macrophages differentiated *in vitro* from control, $\Delta A781_N783$ or P824R PBMCs. Cells were stained for DAPI (blue) and CD68 (red). White arrows indicate dysmorphic macrophages.
- D Immunocytochemistry of macrophages differentiated *in vitro* from control, $\Delta A781_N783$ or P824R PBMCs. Macrophages were stimulated with LPS and exposed to fluorescent opsonised latex beads for 1 h before fixation and quantification of bead⁺ cells via microscopy. Cells were stained using MitoTracker (red) and DAPI (blue).
- E Quantification of phagocytic activity expressed as percentage bead⁺ cells. *P* values were calculated using (***P* = 0.008, **P* = 0.0141, one-way ANOVA with Tukey's multiple comparison test, *n* = 4 assays, error bars indicate SEM).
- F Quantification of macrophages displaying an aberrant morphology as indicated in (c), displayed as percentage of dysmorphic cells per image (****P* < 0.0005, one-way ANOVA with Dunnett's multiple comparison test, data representative of *n* = 2 independent differentiations, with two fields of view imaged per well, error bars indicate SEM).
- G Western blot for CSF-1R in untreated (Unt) BV2 microglia, or BV2 microglia transfected with non-targeting or *Csf-1r* targeting siRNA. Corresponding densitometry (below) representative of technical replicate of *n* = 3 blots (one-way ANOVA with Dunnett's multiple comparison, ****P* = 0.0003, error bars indicate SEM).
- H Immunocytochemistry of untreated and *Csf-1r* siRNA treated BV2 microglia. BV2 microglia were stimulated with LPS and exposed to fluorescent opsonised latex beads for 1 h before fixation and quantification of bead⁺ cells via microscopy. Cells were stained using MitoTracker (red) and DAPI (blue). Arrowheads (white) indicate bead⁺ cells.
- I Quantification of BV2 phagocytic activity expressed as percentage bead⁺ cells (data representative of *n* = 2 independent differentiations, with two fields of view imaged per well, error bars indicate SEM).
- J Immunocytochemistry of microglia isolated from *Csf-1r^{flx/wt};Cx3cr1-Cre⁻* and *Csf-1r^{flx/wt};Cx3cr1-Cre⁺* PO mouse pup brains. Microglia were stimulated with LPS and exposed to fluorescent opsonised latex beads for 1 h before fixation and quantification of bead⁺ cells via microscopy. Cells were stained using MitoTracker (red). Arrowheads (white) indicate bead⁺ cells.
- K Quantification of mouse microglial phagocytic activity expressed as percentage bead⁺ cells (*n* = 4 assays, error bars indicate SEM).
- L Immunocytochemistry of macrophages differentiated *in vitro* from *Csf-1r^{flx/wt};Cx3cr1-Cre⁻* and *Csf-1r^{flx/wt};Cx3cr1-Cre⁺* mouse bone marrow. Macrophages were stimulated with LPS and exposed to fluorescent opsonised latex beads for 1 h before fixation and quantification of bead⁺ cells via microscopy. Cells were stained using MitoTracker (red) and DAPI (blue). Arrowheads (white) indicate bead⁺ cells.
- M Quantification of mouse macrophage phagocytic activity expressed as percentage bead⁺ cells. (**P* = 0.024, Student's *t*-test with Welch's correction, *n* = 4 assays, error bars indicate SEM).

treatment (Fig 5B). To control for the effects of PLX3397 itself on endothelial cells, it was also added to endothelial cells. Although ZO1 and occludin displayed reduced protein levels at 24 h in response to CSF-1R inhibition alone, the critical BBB-associated tight junction protein claudin-5 displayed a microglia-specific response to treatment, with Lo-BVCM reducing protein levels at 24 h (Fig 5C and D). Hi-BVCM induced a downregulation of *Tjp1* expression, as did PLX3397 itself (Fig 5D). Contrastingly, *Ocln* appeared to have been upregulated by untreated microglia conditioned media, an effect which was reduced in response to Lo-BVCM, and ablated completely in the case of Hi-BVCM.

To investigate the interactions in the context of both microglia and endothelial cells having *Csf-1r* heterozygosity, we isolated microglial cells from normal mice (WT) or those lacking a single *Csf-1r* allele in their microglial cells. We collected conditioned medium from these cells in addition to collecting conditioned medium from WT microglial cells where CSF-1R was inhibited using PLX3397. Subsequently, this microglial conditioned medium (MCM) was added to confluent monolayers of primary brain microvascular endothelial cells isolated from WT mice, or mice lacking a single *Csf-1r* allele in their endothelial cells (Fig 5E). Intriguingly, MCM isolated from microglial cells lacking one *Csf-1r* allele could induce a potent downregulation of claudin-5 protein levels (Fig 5F and G). Endothelial cells lacking a single *Csf-1r* allele did not manifest a decreased level of claudin-5 in response to MCM treatment; however, levels of other tight junction components such as occludin and ZO-1 were decreased in a CSF-1R-independent manner (Fig 5C).

To elaborate on the genotype-specific responses observed, we examined transcriptional changes in WT and *Csf-1r^{+/-}* endothelial cells treated with MCM produced by either WT or *Csf-1r^{+/-}* microglia. Expression of TJ components claudin-5, occludin and tricellulin were found to be significantly reduced *Csf-1r^{+/-}* endothelial cells

following treatment with *Csf-1r^{+/-}* MCM (Fig 5H–O). Wild-type endothelial cells also displayed a resistance to *Csf-1r^{+/-}* MCM, maintaining tight junction gene expression (Fig 5H–O). With regard to expression of CSF-1R pathway components, transcription of both *Csf-1* and *Il34* was elevated in *Csf-1r^{+/-}* endothelial cells and in the case of *Il34*, *Csf-1r^{+/-}* MCM induced an upregulatory response in *Csf-1r^{+/-}* endothelial cells. In contrast, *Csf-1r^{+/+}* MCM inhibited *Il34* expression in *Csf-1r^{+/-}* endothelial cells, suggesting microglia may regulate endothelial *Il34* expression in a CSF-1R dependent manner (Fig EV4A and C). The response of the macrophage inhibitory factor (*Mif*) expression was similar to that of *Il34*, with an upregulation of endothelial *Mif* expression only observed in *Csf-1r^{+/-}* endothelial cells treated with *Csf-1r^{+/-}* MCM (Fig EV4F). Upregulation of *Mif* expression has been implicated in the activation of microglial-mediated inflammatory processes and has recently been proposed to be a biomarker of Alzheimer's disease (Zhang *et al*, 2016, 2019). Furthermore, MIF expression has been demonstrated to enhance tight junction breakdown and blood–brain barrier permeability in stroke (Liu *et al*, 2018), and MIF-mediated processes are reported to be significantly altered in ALSP frontal cortex white matter (Kempthorne *et al*, 2020). The restriction of these transcriptional changes in TJ components, *Il34* and *Mif* to *Csf-1r^{+/-}* endothelial cells responding to soluble factors from *Csf-1r^{+/-}* microglia indicates CSF-1R as a key regulator of microglial-endothelial crosstalk.

CSF-1R mutations and inhibition induce blood–brain barrier disruption

Given the evidence of CAA and the cerebrovascular pathology apparent in each post-mortem ALSP case we examined, we stained post-mortem ALSP brain sections for claudin-5, a key mediator of tight junction function at the BBB. In areas of dense amyloid-beta




Figure 4. CSF-1R expression in endothelial cells and macrophages affects response to amyloid injection.

- A** Immunohistochemistry of *Csf-1^{flx/wt};Cx3cr1-Cre⁻* (top) and *Csf-1^{flx/wt};Cx3cr1-Cre⁺* (bottom) mice unilaterally injected with A β 1-42 in the hippocampus and stained for IB4 (green), F4/80 (white) and A β (red). Scale bars indicate 50 μ m.
- B** Quantification of F4/80 and IB4 immunopositivity following intrahippocampal injection of A β 1-42. Quantification of immunopositivity in both injected and uninjected hippocampi of *Csf-1^{flx/wt};Cx3cr1-Cre⁻* and *Csf-1^{flx/wt};Cx3cr1-Cre⁺* mice. (Two-way ANOVA with Sidak's test for multiple comparisons. Asterisks (*) indicate comparison to immunopositivity values of the uninjected hippocampus, obliques (#) indicate comparison between *Csf-1^{flx/wt};Cx3cr1-Cre⁻* and *Csf-1^{flx/wt};Cx3cr1-Cre⁺* mice, ## or ** $P < 0.003$, ### or **** $P < 0.0001$, $n = 5$ mice per group, error bars indicate SEM.)
- C** Immunohistochemistry of *Csf1^{wt/flx};Tie2-Cre⁻* (top) and *Csf1^{wt/flx};Tie2-Cre⁺* (bottom) mice unilaterally injected with A β 1-42 in the hippocampus and stained for IB4 (green), F4/80 (white) and A β (red).
- D** Quantification of F4/80 and IB4 immunopositivity following intrahippocampal injection of A β 1-42. Quantification of immunopositivity in both injected and uninjected hippocampi of *Csf-1^{wt/flx};Tie2-Cre⁻* and *Csf-1^{wt/flx};Tie2-Cre⁺* mice. ($n = 5$ mice per group. Two-way ANOVA with Sidak's test for multiple comparisons. Asterisks (*) indicate comparison to immunopositivity values of the uninjected hippocampus, * $P < 0.01$, *** $P < 0.0005$, error bars indicate SEM.)

deposition around blood vessels, we observed a non-linear distribution of claudin-5 (Fig 6A) in tandem with extravasation of IgG (Fig 6B) and fibrinogen (Fig 6G) suggestive of BBB disruption. Perivascular localisation of CD68- and CD163-positive cells (Fig 6E and F) indicated a recruitment of macrophages to the vasculature. Added to this, there were also large swathes of GFAP immunoreactivity (Fig 6C and D) in areas of CAA, suggestive of perivascular astrogliosis absent in age-matched controls (Appendix Fig S2). Given the very clear cerebrovascular pathology observed in these post-mortem cases, we conducted dynamic contrast-enhanced MRI (DCE-MRI) in a genetically diagnosed patient with ALSP who had recently become symptomatic ($\Delta A781_N783$). While the patient had clear periventricular FLAIR enhancements, there was also clear evidence of BBB disruption in the cortical and deep white matter regions of the brain

(Fig 6H and I). Susceptibility weighted imaging (SWI) showed evidence of iron deposition in the putamen and in a similar pattern to BBB disruption (Fig 6J).

Given the dysregulated BBB phenotype in life and in post-mortem ALSP samples and as CSF-1R can differentially regulate endothelial-microglial crosstalk, we wanted to elucidate the impact of disrupted CSF-1R signalling in brain endothelial cells. In this regard, a dose-dependent decrease in claudin-5 and occludin levels were observed at 24-h post-stimulation of cells with a known CSF-1R inhibitor PLX3397 (Fig EV5A and B). This decrease in tight junction components was accompanied by a concomitant decrease in transcription of both *Cld5* and *Ocln* at 24 h, which is maintained through 48 h in the case of *Ocln*. PLX3397 treatment resulted in an increase in paracellular flux of FD-4 across a polarised monolayer of




Figure 5. Endothelial–macrophage crosstalk regulates CSF-1R expression and TJs.

- A Schematic for experimental design.
- B Western blot for CSF-1R in b.End3 cells treated with different BV2 conditioned media or PLX3397, with corresponding densitometry (right). ($n = 3$ independent BV2 media conditionings and b.End3 treatments, one-way ANOVA with Dunnett's post-test for multiple comparisons, $*P < 0.05$, $***P < 0.0005$, error bars indicate SEM).
- C Western blot for tight junction proteins in b.End3 cells treated with unconditioned, microglia conditioned media or PLX3397.
- D Densitometry of tight junction protein changes (top) and transcriptional changes in *Tjp1*, *Ocln* and *Cld5* (bottom) following conditioned media treatments or 20 μM PLX3397. ($n = 3$ independent BV2 media conditionings and b.End3 treatments, one-way ANOVA with Dunnett's post-test for multiple comparisons, $*P < 0.05$, $**P < 0.009$, error bars indicate SEM).
- E Schematic for experimental design.
- F Western blot of WT endothelial cells treated with unconditioned or microglia conditioned media (MCM) produced from *Csf1r*^{+/-} or PLX3397-inhibited microglia.
- G Western blot of *Csf1r*^{+/-} endothelial cells treated with unconditioned, *Csf1r*^{+/-} MCM or PLX3397 MCM.
- H–K qPCR of wild type (blue) or *Csf1r*^{+/-} (red) endothelial cells treated with control, *Csf1r*^{+/+} MCM or *Csf1r*^{+/-} MCM. Statistical analyses of inter-genotype changes. ($****P < 0.0001$, $**P < 0.005$, Scatter plots represent technical replicates of $n = 2$ independent primary cell isolations and microglia conditionings, Two-way ANOVA with multiple comparisons and Sidak's post-test, error bars indicate SEM).
- L–O qPCR of wild type (blue) or *Csf1r*^{+/-} (red) endothelial cells treated with control, *Csf1r*^{+/+} MCM or *Csf1r*^{+/-} MCM. Statistical analyses of changes relative to respective untreated Control. ($**P < 0.005$, $*P < 0.05$. Scatter plots represent technical replicates of $n = 2$ independent primary cell isolations and microglia conditionings, two-way ANOVA with multiple comparisons and Sidak's post-test, error bars indicate SEM).




Figure 6. Loss of CSF-1R reduces BBB integrity.

A–C (A) IHC of ALSP patient post-mortem tissue for amyloid- β (green) and CLD5 (red), (B) human IgG (green) and PDGFR β (red), (C) GFAP (green) and CLD5 (red). Δ A781_N783 and P824R indicate the CSF-1R variant present.
 D–H (D) Iba1 (green) and GFAP (red), (E) amyloid- β (green) and CD68 (red), (F) CD163 (green) and CLD5 (red), (G) fibrinogen (green) and CLD5 (red) and (H) FLAIR imaging of an ALSP patient with the Δ A781_N783 CSF-1R variant. Δ A781_N783 and P824R indicate the CSF-1R variant present.
 I T1-weighted DCE-MRI of an ALSP patient with the Δ A781_N783 CSF-1R variant. Colormetric scale indicates the slope of the quantified Gd-BOPTA accumulation, as an indicator of BBB permeability.
 J Susceptibility weighted imaging (SWI) of an ALSP patient with the Δ A781_N783 CSF-1R variant showing iron deposition.

Data information: Note that Fig 6C and F are shown again in Fig EV1 for ease of comparison.

primary brain endothelial cells (Fig EV5E) and accompanying down-regulation of *Cld5* (Fig EV5D). While endothelial expression of CSF-1R is disputed, these data provide a tentative link between CSF-1R inhibition and tight junction integrity. Further *in vivo* characterisation of the BBB in the endothelial *Csf1r*^{-/-} mouse will be needed to directly attribute endothelial CSF-1R loss with a corresponding loss in TJ integrity within the cerebrovasculature.

Discussion

Within the healthy brain, microglia are the primary cells that respond to CSF-1 and IL-34. Following ligation to CSF-1R, the ligand is taken into the cell, reducing the extracellular concentration and preventing long-term local CSF-1R activity. Within the brain of an individual with ALSP however, microglia will constitutively express 50% less functional CSF-1R. This likely results in a CNS saturated with IL-34 and CSF-1 and increased levels of CSF-1 have previously been observed in the CSF-1R-knockout mouse and indeed in some mouse models of AD (Dai *et al*, 2002; Laske *et al*, 2010). This increased pool of CSF-1R ligands may also provide a prolonged opportunity for other cells expressing the receptor to bind ligand and signal through CSF-1R. Therefore, to date, a major focus has

been to understand and potentially target CSF-1R signalling in microglial cells in the context of neuropathologies such as AD and epilepsy.

Here, we sought to understand the role of CSF-1R signalling in microglial cells in the context of haploinsufficiency of CSF-1R. We were, however, surprised to find that microglial cells seemed to adequately tolerate CSF-1R depletion and it was peripheral macrophages and endothelial cells that appeared to be impacted more profoundly. This suggests that, at least in the context of ALSP, the primary driving force of pathology is at the level of the systemic immune response to CSF-1R depletion. Intriguingly, the development of CAA has been shown to occur in up to 80% of sporadic AD cases; however, the underlying molecular aetiology of A β deposition around blood vessels is still far from clear. Here, we show that in genetically diagnosed cases of ALSP, CAA development is clear and evident in each case. Added to this, we now confirm that there is no dominant-negative effect of the CSF-1R mutations and they simply lead to a loss of function in kinase activity.

Our findings suggest that inhibiting CSF-1R signalling as previously proposed as a potential therapeutic for AD (Dagher *et al*, 2015; Spangenberg *et al*, 2019) could in fact exacerbate the human pathology. CSF-1R inhibition could potentially impact the phagocytic capacity of macrophages in addition to reducing peripheral

macrophage-mediated clearance of vascular amyloid- β . Secondly, attenuated and aberrant microglial CSF-1R signalling will induce endothelial tight junction re-modelling and BBB permeability as we have shown in post-mortem ALSP cases in addition to contrast-enhanced MRI studies in a genetically diagnosed ALSP patient. Our findings suggest a targeted approach to restoring BBB integrity while also restoring CSF-1R signalling in macrophages could drive a therapeutic response in ALSP patients and other AD-like dementia.

We now propose that symptomatic and genetically diagnosed individuals with ALSP and potentially other forms of AD-like neuropathology will respond to CSF-1R and BBB stabilising approaches to therapy as opposed to CSF-1R inhibition-based strategies as currently proposed. Interestingly, our data also strongly suggest that ALSP patients may be amenable and highly responsive to bone marrow transplantation, with transplantation potentially slowing the course of neurodegeneration. This has recently been evidenced in a small series of case reports where ALSP patients have been shown to stabilise in the months and years after receiving transplantation for alternative perceived reasons (Mochel *et al*, 2019; Gelfand *et al*, 2020). Understanding the molecular aetiology of rare neurodegenerative conditions such as ALSP may be the driving force in identifying novel therapeutic approaches to more common neuropathies. The suggestion of microglial cells being a central driving force of pathology should also be revised to incorporate the critical role played by macrophages and endothelial cells.

Materials and Methods

DNA isolation

DNA was isolated from whole blood of live ALSP patients, or from formalin-fixed paraffin embedded (FFPE) tissue. For whole blood, 2 ml of peripheral blood was added to 2 ml of red blood cell (RBC) lysis buffer (0.32 M sucrose, 10 mM Tris, 5 mM MgCl₂, 0.75% v/v Triton X-100, pH 7.4). The mixture was inverted and placed on ice for 3 min and spun at 1,500 g for 15 min at 21°C. The supernatant was discarded, and pellet resuspended in 2 ml RBC lysis buffer and 6 ml dH₂O before being centrifuged again. The washed pellet was resuspended in proteinase K digest buffer (20 mM Tris, 4 mM Na₂EDTA, 100 mM NaCl, 1% w/v SDS, 0.2 mg/ml proteinase K pH 7.4) and incubated at 55°C overnight. 4 ml of 5.3 M NaCl was added to the completed digest followed by 0.2 volumes of chloroform. Tubes were shaken, centrifuged, and the upper aqueous layer moved to a new tube. DNA was isolated using alcohol precipitation followed by resuspension in nuclease free water.

FFPE brain tissue was incubated with gentle shaking in xylene for 15 min at 21°C, centrifuged at 1,500 g for 5 min at 21°C, and supernatant was removed and replaced with fresh xylene. This was repeated twice before pelleted tissue was rehydrated by incubating in decreasing concentrations of ethanol, 100, 70, 50% before incubating in dH₂O. As above, the pelleted tissue was incubated overnight in proteinase K digest buffer and DNA was isolated.

100 ng of DNA was amplified by PCR in a volume of 25 μ l using 1 \times reaction buffer, 200 μ M each of dNTPs, 0.2 μ M of forward and

reverse primers, and 1.25 units of DNA Taq polymerase under the following conditions: 95°C 5 min; (95°C 1 min; 58°C 1 min; 72°C 1 min) \times 34; 72°C 5 min; 4°C hold. This produced an amplified product of 603 bp using the following primers: forward primer 5'-CTCCAGCAGGGACTCCAAAG-3' and reverse primer 5'-GGATGCCA TAGGACCAGAC-3'. DNA from the above amplification was purified using a QIAquick PCR purification kit (Qiagen) and subjected to direct sequencing using the forward primer (above).

Generation of CSF-1R-expressing constructs

For *in vitro* work, Native, and Δ A781_N783 CSF-1R cDNA sequences were synthesised using GeneArt (Thermo Fisher Scientific) and cloned into the AgeI/EcoRI site of the pcDNA3-EGFP expression plasmid (Addgene). The P824R expression construct was generated from the native CSF-1R expression plasmid using the Q5[®] Site-Directed Mutagenesis Kit (New England Biolabs) and the following primers: forward 5'-TGGATGGCCCGAGAGAGCATCTTTG-3' and reverse 5'-CTTCACAGGCAGGCGGC-3'.

MRI

BBB permeability maps were created using the slope of contrast agent concentration in each voxel over time, calculated by a linear fit model as previously described. Thresholds of high permeability were defined by the 95th percentile of all slopes in a previously examined control group. All imaging was performed using a 3T Philips Achieva scanner and included a T1-weighted anatomical scan (3D gradient echo, TE/TR = 3/6.7 ms, acquisition matrix 268 \times 266, voxel size: 0.83 \times 0.83 \times 0.9 mm), T2-weighted imaging (TE/TR = 80/3,000 ms, voxel size: 0.45 \times 0.45 \times 0.4 mm), FLAIR (TE/TR = 125/11,000 ms, voxel size: 0.45 \times 0.45 \times 4 mm).

The calculation of pre-contrast longitudinal relaxation time (T₁₀), the variable flip angle (VFA) method was used (3D T1w-FFE, TE/TR = 2.78/5.67 ms, acquisition matrix: 240 \times 184, voxel size: 0.68 \times 0.68 \times 5 mm, flip angles: 2, 10, 16 and 24°). Dynamic contrast-enhanced (DCE) sequence was then acquired (Axial, 3D T1w-FFE, TE/TR = 2.78/5.6 ms, acquisition matrix: 240 \times 184, voxel size: 0.68 \times 0.68 \times 5 mm, flip angle: 6°, Δ t = 6.5 s, temporal repetitions: 70, total scan length: 7.6 min). An intravenous bolus injection of the contrast agent gadobenate dimeglumine (Gd-BOPTA, Bracco Diagnostics Inc., Milan, Italy) was administered using an automatic injector after the first three DCE repetitions. All ethical approvals were in place prior to the initiation of studies on human subjects. All experiments conformed to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report.

Cell line culture

Human embryonic kidney cells (HEK293, ATCC) were cultured in Dulbecco's modified Eagle's medium containing 4,500 mg/l glucose, GlutaMAX and 110.0 mg/ml sodium pyruvate (DMEM) supplemented with 10% foetal bovine serum (FBS) in a 5% CO₂ incubator at 37°C. One day before transfection, HEK293 cells were seeded on 12-well plates (2.5 \times 10⁵ cells per well). The next day, 500 ng of plasmid containing wild-type or variant CSF-1R cDNA was transfected per well using Lipofectamine 2000 (Invitrogen).

For signalling experiments, transfected cells were incubated in DMEM without serum for 16 h. IL-34 or CSF-1 was added at 10, 50 or 100 ng/ml and cells were incubated for 10 min. Cells were washed with PBS on ice and proteins were isolated with lysis buffer (50 mM Tris, 150 mM NaCl, 0.5% w/v sodium deoxycholate, 0.1% v/v Triton X-100 and 0.1% w/v SDS) with added cOmplete™, Mini Protease Inhibitor Cocktail (Roche). For treatment with protein turnover regulators, cells were treated 24 h after transfection with rapamycin (0.1, 0.5, 1, 5 and 10 μ M), 3-MA (0.1, 0.2, 0.5, 1 mM) or MG132 (0.1, 0.5, 1, 5 μ M). Cells were lysed as above at 24 h post-treatment for rapamycin and 3-MA and at 7 h post-treatment for MG132. For the MG132 pre-treated signalling experiment, cells were treated 24 h post-transfection for 1 h in 1 μ M MG132 before being treated with 10, 50 or 100 ng/ml CSF-1 for 10 min and lysed as above.

The mouse microglial BV2 cell line was kindly provided by the Lynch lab (TCIN, Trinity College Dublin). Cells were grown in DMEM with 10% FBS in a 5% CO₂ incubator at 37°C, and plated in 1 ml of media at 1.25×10^6 cells per T25 flask for media conditioning. Flasks were flooded with 12 ml DMEM, 10% FBS 2 h later. At 24 h postseeding, media was refreshed and BV2 cells grown for 48 h to generate conditioned media. Conditioned media was centrifuged at 300 g for 5 min at 21°C, the supernatant passed through a 0.2 μ m sterile filter and added to endothelial cultures.

Mouse brain endothelial cells (Bend.3, ATCC) were cultured in DMEM supplemented with 10% FBS in a 5% CO₂ incubator at 37°C. Bend.3 cells were seeded on 12-well plates (2.5×10^5 cells per well) and allowed to grow to confluency and treated with BV2-conditioned media for 24 h. Cells were lysed for protein analysis as above, and in TRK Lysis buffer (Omega Bio-tek) for RNA isolation. Transfection with *Csf-1r* Smart Pool (Dharmacon) siRNA was performed 24 h after cell seeding using Viromer Blue transfection reagent (Lipocalyx) and 20 pmol siRNA per well.

Immunocytochemistry

HEK293 cells were seeded on 1% fibronectin-coated 1.3 mm tissue culture coverslips (Sarstedt) in DMEM, 10% FBS. After plasmid transfection, cells were fixed for 10 min at room temperature with ice-cold methanol, washed twice with PBS and incubated with 5% normal goat serum (NGS) before overnight incubation with polyclonal rabbit anti-CSF-1R (Invitrogen; PA5-25974, 1:100) at 4°C. Cells were then washed twice with PBS and incubated with Cy3-conjugated goat anti-rabbit IgG secondary antibody (1:500; Abcam) for 2 h at room temperature and counterstained with Hoechst 33258 to visualise nuclei.

Macrophages were seeded in poly-L-lysine coated 8-well chamber slides (Ibidi) at 2.8×10^4 cells/cm². Macrophages were grown for 72 h, fixed in 4% PFA for 10 min at RT and stained as above with rat anti-human CD68 (Abcam) primary antibody and 594-conjugated goat anti-rat IgG secondary antibody (Invitrogen).

Immunohistochemistry

FFPE sections of autopsied HDLS brains were de-paraffinised in xylene and rehydrated stepwise through decreasing ethanol concentrations. Sections were permeabilised by incubating in methanol for 15 min at -20°C and blocked in 5% NGS, PBS, 0.1%

Triton X-100 for 45 min. Sections were incubated in primary antibody in PBS, 1% NGS, 0.1% Triton X-100 overnight at 4°C (CD68 (Santa Cruz, sc-20060, 1:100), anti-beta-amyloid AW7 (kindly provided by Dominic Walsh, 1:1,000), CLD5 (Invitrogen, 34-1600, 1:200), CD163 (Novocastra, NCL-CD163, 1:200), GFAP (Sigma, G3893, 1:500), hIgG (Abcam, 97170, 1:300), Fibrinogen (DAKO, F0111, 1:300), Iba1 (Wako, 019-19741, 1:500)). Slides were washed three times in PBS and incubated with 594- and 488-conjugated goat anti-rabbit and anti-mouse secondary antibodies (1:500; Invitrogen) for 3 h at 21°C and counterstained with Hoechst 33258 to visualise nuclei.

For IHC of amyloid-injected brains, mice were killed and the brains quickly removed and embedded in optimal cutting temperature compound (VWR), snap-frozen in liquid nitrogen and stored at -20°C prior to slicing on a cryostat. Mouse brain cryosections (20 μ m thick) were post-fixed in ice-cold methanol for 10 min at room temperature and washed three times in PBS. Sections were then incubated with 5% NGS before overnight incubation with primary antibodies at 4°C (F4/80 (Abcam; ab6640, 1:100), anti-beta-amyloid AW7 (kindly provided by Dominic Walsh, 1:1,000)). Sections were double-stained with isolectin-IB4-Alexa Fluor 488 1:300 (Life Technologies), to label vessels and macrophages. Following three washes in PBS, sections were incubated with Cy3-conjugated goat anti-rabbit IgG and 405-conjugated goat anti-rat secondary antibody (1:500; Abcam) for 2 h at room temperature, washed three times with PBS and counterstained with Hoechst 33258. Sections were mounted and with Aqua Polymount (Polysciences). Sections were imaged with a Zeiss LSM 710 confocal laser scanning microscope. For quantification, pixel intensity was thresholded uniformly across all images and the ratios of pixel intensity values between the injected and uninjected hippocampus were compared. All image analysis was performed using ImageJ (National Institutes of Health, Rockville, MD, USA).

SDS-PAGE and Western Blotting

Whole cell lysates were diluted in dH₂O and 5X Pierce™ Lane Marker Reducing Sample Buffer (Thermo Fisher) and 10 μ g total protein loaded per well for separation by SDS-PAGE. Gels were transferred onto methanol-activated polyvinylidene difluoride (PVDF) membranes (Immobilon-P Transfer Membrane, Merck Millipore) via semi-dry transfer. Transferred membranes were re-activated with methanol and blocked under slight agitation in TBS-Tween-20 containing 3% w/v Marvel non-fat dry milk for 1 h at room temperature. Blocked membranes were washed three times with TBS-Tween-20 and treated with primary antibody overnight at 4°C (CLD5 (Invitrogen, 34-1600, 1:1,000), ZO1 (Invitrogen, 402200, 1:1,000), OCLN (Novus Biotech, NBP1-87402, 1:1,000), Triellulin (Invitrogen, 488400, 1:1,000), GAPDH (Cell Signalling, 2118, 1:4,000), phospho-ERK (Cell Signalling, 9101, 1:2,000), total ERK (Cell Signalling, 9102, 1:1,000), CSF-1R (Abcam, ab221684, 1:1,000), β -ACTIN (Abcam, ab8227, 1:4,000)). Membranes were washed three times for 5 min in TBS-Tween-20 and incubated with horse radish peroxidase (HRP)-conjugated goat anti-rabbit secondary antibody (Sigma) diluted 1:2,000 in TBS-Tween-20 for 2 h at room temperature. Secondary antibody was removed and membranes were washed four times for 5 min in TBS-Tween-20. Blots were developed by enhanced chemiluminescence (ECL). A 1:1

mix of WesternBright ECL Luminol/enhancer solution and Peroxide Chemiluminescent solution (Advantsta) was incubated at room temperature for 2 min before being directly added onto washed blots. The LiCor C-Digit Blot Scanner was used to detect chemiluminescence over a 12 min exposure time.

FACS

PBMCs isolated from HDLS donor blood were seeded in round bottomed 96-well plates in Roswell Park Memorial Institute (RPMI) media with 10% FBS at 4×10^5 cells per well and incubated in a 5% CO₂ incubator at 37°C overnight. Cells were centrifuged at 300 g for 5 min and blocked for 10 min with 50 µl 10% human AB serum, 1% FBS in PBS. Blocked PBMCs were incubated in Live/Dead Aqua (1:500; Life technologies (Fisher/Invitrogen) L34957) for 30 min, washed in PBS and incubated in fluorochrome-labelled primary antibody diluted 1:10 in PBS, 1% FBS for 20 min at 4°C. (Lin FITC (BioLegend 348801), CD3 PerCP (Miltenyi 130-100-458), CD19 APCy7 (Miltenyi 130-098-073), CD14 PacBlue (Miltenyi 130-098-058). Cells were washed twice with PBS 1% FBS and analysed by flow cytometry immediately. Gating during analysis was based on fluorescence minus one controls. Flow cytometry was carried out on a BD LSRFortessa cell analyser and analysed using FlowJo software (Tree Star).

Primary mouse cerebral microvessel isolation and culture

Microvessels were isolated from cortical grey matter of experimental mice by collagenase/dispase (Roche) digestion and bovine serum albumin density gradient centrifugation. Purified vessels were seeded onto collagen IV/fibronectin-coated tissue culture plates or Corning (Corning) HTS 24-well Transwell polyester inserts (0.4 µm pore size, vessels from five mouse brains per 3 ml) at high density. Cells were grown in EGM2-MV (Lonza) (with 5 µg/ml puromycin during the first 3 days for endothelial cell selection) for 2–3 weeks until their transendothelial electrical resistance values plateaued.

Transwell permeability assays

Mouse brain endothelial cells (5×10^4 cells per well) were grown to confluence on 1% fibronectin-coated Corning HTS 24-well Transwell polyester inserts with a pore size of 0.4 µm and treated with PLX3397 for 24 h. 200 µl of 1 mg/ml of FITC–4kDa Dextran (Sigma-Aldrich) in EGM2-MV2 was added to the apical chamber of each well, and the cells were incubated at 37°C. Sampling aliquots were taken from the basolateral chamber and replaced with fresh medium every 15 min for 2 h and then transferred to 96-well plates (Nunc). FITC-Dextran fluorescence was determined using a spectrofluorometer (Optima Scientific) at an excitation wavelength of 485 nm and an emission wavelength of 520 nm. Relative fluorescence units were converted to values of nanograms per millilitre, using FITC-Dextran standard curves, and were corrected for background fluorescence and serial dilutions over the course of the experiment. The apparent permeability coefficient (Papp) for each treatment was calculated using the following equation:

$$\text{Papp}(\text{cm/s}) = (\text{dQ/dT})(A \times C_0)$$

where dQ/dT (µg/s) is the rate of appearance of FITC-Dextran on the receiver side after application, A (cm²) is the effective surface area of the insert size, and C₀ (µg/ml) is the initial FITC-Dextran concentration on the donor side. dQ/dT is the slope m ($y = mx + c$) calculated by plotting the cumulative amount (Q) versus time (s).

Primary mouse microglia isolation and culture

Microglia were isolated as described in Cox *et al.* (Cox *et al.*, 2015). Whole brains were dissected from *Cx3Cr1-Cre^{+/-};Csf-1^{wt/Flx}* or *Cx3Cr1-Cre^{-/-};Csf-1^{wt/Flx}* littermates, chopped and added to working media (DMEM GlutaMAX containing 10% FBS, and penicillin/streptomycin (10 µg/ml). Brains were homogenised using a 5 ml pipette, passed through a 40 µm sterile mesh filter, and spun at 300 g for 5 min at 21°C. Pelleted cells were resuspended in working media, plated in 1 ml per T25 flask and incubated in a humidified environment at 37°C, 5% CO₂. 5 ml of working media was added 3 h later following cell attachment. After 24 h, media was supplemented with 20 ng/ml colony stimulating factor 1 (CSF-1) and 10 ng/ml colony stimulating factor 2 (CSF2) (R&D Systems). Mixed glial cultures were grown for 14 days, changing media every 4 days. On day 14, flasks were wrapped with parafilm and shaken at 110 rpm at 21°C for 1 h to isolate nonadherent microglial cells. Suspended cells were centrifuged at 300 g for 5 min at 21°C seeded at 5×10^4 cells/cm² in minimal volumes of working media and grown in a 5% CO₂ incubator at 37°C. After 2 h, working media containing any unattached cells was removed and replaced.

For media conditioning, 7.3×10^5 cells were seeded into 6-well tissue culture plates. Microglia were grown for 24 h and had media replaced and collected 24 h later. Conditioned media was centrifuged, sterile filtered and diluted at a 2:1 ratio in EGM2-MV2 before adding to endothelial cultures.

BMDM isolation

Femurs and tibiae were removed from *Cx3Cr1-Cre^{+/-};Csf-1^{wt/Flx}* or *Cx3Cr1-Cre^{-/-};Csf-1^{wt/Flx}* adult mice and the fat and muscles cut away to leave clean bones. A 20-ml syringe was filled with DMEM + Glutamax medium supplemented with 10% FCS and 1% P/S, a 27 G needle attached, and the bone marrow was flushed through the bones into a sterile Petri dish. Aggregates were broken up by passing the cells repeatedly through a 20-ml syringe with a 19 G needle attached. The cells were transferred to a 50-ml tube and centrifuged at 300 g for 5 min. Cells were resuspended in the medium with 25 ng/ml colony stimulating factor CSF-1 and plated into 6 dishes/mouse, with 10 ml of media per mouse. Plates were incubated at 37°C with 5% CO₂. Cells were fed on day 3 by adding 10 ml of medium with 25 ng/ml of M-CSF per dish. On day 6, trypsin-EDTA was used to remove the cells from the dishes. Cells were seeded onto 13mm tissue culture coverslips and allowed to grow for 24 h before use.

PBMC isolation and macrophage differentiation

Whole blood was collected in EDTA-coated tubes and diluted 1:1 with PBS, 2% FBS. 20 ml of the blood/PBS mixture was layered onto 10 ml of Lymphoprep (Stemcell Technologies) and centrifuged at 400 g for 45 min with brake and acceleration set to zero. The

plasma layer was removed and PBMCs collected using a Pasteur pipette and washed twice in PBS, 2% FBS followed by a final wash in RPMI. Cells were resuspended in RPMI, 50% FBS, 10% DMSO and frozen.

To generate macrophages, PBMCs were thawed and transferred to complete RPMI, 20% heat-inactivated FBS, 50 ng/ml CSF-1 (cRPMI) and grown for 48 h, rinsed 3 times with RPMI to remove loosely adhered cells and allowed to grow in cRPMI until cells expanded to confluency, changing media every 2 days. Differentiated macrophages were trypsinised and seeded at 2.8×10^4 cells/cm².

Phagocytosis assay

Microglia, BMDM and PBMC-derived macrophages were treated with 10 ng/ml lipopolysaccharide (LPS) for 24 h prior to being assayed. Latex beads, polystyrene amine modified (yellow-green) (Sigma) were pre-opsonised in FBS (1:5) at 37°C for 1 h. Opsonised beads were diluted 1:10,000 in media and added to cells for 1 h. Cells were washed with ice-cold PBS 3 times to remove surface bound beads and fixed in 4% PFA for 10 min and stained with MitoTracker Orange CMTMRos for 30 min. Fixed cells were imaged on a Zeiss LSM 710 confocal microscope. Images were analysed by counting bead⁺ cells in multiple fields of view over 4 replicates and the data expressed as % bead⁺ cells per genotype.

Intrahippocampal AB1-42 injection

Mice (8–12 weeks old) were anaesthetised using a ketamine/meta-domidine mixture administered via intraperitoneal injection and placed in a stereotaxic frame. An incision was made to expose the skull, and burr holes were made using a surgical drill either above the dorsal hippocampus or the medial prefrontal cortex (mPFC). AggreSure™ Beta-Amyloid 1–42 (AnaSpec) was reconstituted in 50 mM Tris, 150 mM NaCl, pH 7.2 at 0.25 mg/ml per manufacturer's instructions. A Hamilton syringe was loaded with 10 µl reconstituted amyloid, and the needle was slowly lowered into the dorsal hippocampus: (co-ordinates: A/P = −1.9 mm; M/L = ±1.55 mm; D/V = 1.75 mm). 5.0 µl of Beta-Amyloid 1-42 was then injected at a rate of 0.5 µl per min, and once complete, the needle was left in place for 5 min. Anaesthesia was reversed with an intraperitoneal injection of atipamezole and placed in an incubator until recovered. Mice were sacrificed 3 days post-injection and brains taken for IHC.

Quantitative real-time PCR

RNA was isolated using the E.Z.N.A. Total RNA Kit I (Omega Biotek) and cDNA synthesis was performed using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). cDNA was diluted 1:10 with nuclease free water and quantitative RT-PCR was performed on a StepOnePlus (Applied Biosystems) machine using SensiFAST™ SYBR® Hi-ROX Kit (Bioline) and primers listed in Table 1. Cycle threshold (Ct) values were to β-actin and to untreated controls using the delta cT method.

Stress and toxicity microarray

HEK293 cells were transfected with native or P824R CSF-1R-expressing plasmids and lysed at 24 h post-transfection in TRK

Table 1. RT-PCR primer sequences.

Gene symbol	Forward primer (5'–3')	Reverse primer (5'–3')
<i>Cld5</i>	TTTCTTCTATGCGCAGTTGG	GCAGTTTGGTGCTACTTCA
<i>Ocln</i>	ACAGTCCAATGGCCTACTCC	ACTTCAGGCACCAGAGGTGT
<i>Tjp1</i>	GCATGTTCAACGTTATCCAT	GCTAAGAGCACAGCAATGGA
<i>Marveld2</i>	CTGAGAATCTGGGTGTGGT	ACGAGTACGAAGGGGGTCTT
<i>Actb</i>	GGGAAATCGTGCGTGACAT	GTGATGACCTGCGCGTCAG
<i>Csf-1</i>	AGTGCTCTAGCCGAGATGTGGT	CAGAGGCCGGTCACTGCTA
<i>Csf-1r</i>	AAGCAGAAGCCGAAGTACCA	GTCCCTGCGCACATATTTTCAT
<i>Il-34</i>	CGTACAGCGGAGCCTCATGGAT	CAGCTCGCAGTCTGCCATTTT
<i>Mif</i>	GCCAGAGGGGTTTCTGT	GTTCTGCGCGTAAAG
<i>Icam1</i>	TGTCAGCCACCATGCCTTAG	CAGCTTGACGACCCCTTCTA
<i>Ptprz1</i>	AATAGCCCAAAGCAGTCTCC	CCGATCCTTCAGATGACACA

lysis buffer. RNA was isolated and cDNA synthesised using the RT² First Strand Synthesis Kit (Qiagen), with DNase I digests and genomic DNA elimination steps included. Native and P824R-transfected cell cDNA were analysed using the RT² Profiler™ PCR Array Human Stress & Toxicity PathwayFinder (Qiagen) per manufacturer's instructions.

Statistical analyses

GraphPad Prism 8.0 (GraphPad Software) was used for statistical analyses. Statistical analysis was performed using Student's *t*-test, with significance represented by a *P* value of ≤ 0.05. For multiple comparisons, ANOVA was used with a Dunnett post-test and significance represented by a *P* value of ≤ 0.05. The omnibus K2 (D'Agostino-Pearson) test was used in GraphPad Prism 8 to test for Gaussian distribution of data. G*Power was used a priori to calculate an appropriate sample size to ensure adequate power for experiments. All animal experiments were conducted in a blinded fashion, with the analysis similarly performed by an experimenter blinded to the conditions. Randomisation was used for any experiments using injected material such as amyloid-β. Littermate controls were used for knockout studies and retroactively genotyped.

Animals

All studies carried out in the Smurfit Institute of Genetics in Trinity College Dublin (TCD) adhere to the principles laid out by the internal ethics committee at TCD and all relevant national licences were obtained prior to commencement of all studies. All mice were bred on-site in the specific pathogen-free unit at the Smurfit Institute of Genetics in TCD.

Data and software availability

This study includes no data deposited in external repositories.

Expanded View for this article is available online.

The paper explained

Problem

Leucoencephalopathies are a class of progressive diseases of the white matter of the brain which can be either acquired over life or the product of an inherited genetic mutation. Adult-onset leucoencephalopathy with axonal spheroids and pigmented glia (ALSP) accounts for up to a quarter of reported adult-onset leucodystrophies. Despite the rapid and fatally progressive nature of ALSP, there has yet to be an effective treatment for the disease. Caused by mutations in the *CSF1R* gene, which is essential for microglial viability, ALSP is widely considered to be a microgliopathy. Here, we present an alternative approach to the aetiology of the disease which brings into consideration the blood–brain barrier (BBB) and peripheral macrophage populations.

Results

Through examining post-mortem cortical samples, we identified two familial ALSP cohorts heterozygous for novel *CSF1R* mutations and presenting with an additional pathology of cerebral amyloid angiopathy (CAA) and BBB breakdown. With these results indicative of a BBB component to ALSP, we sought to characterise the *CSF1R* mutations driving this novel secondary pathology. Through *in vitro* analyses of variant CSF-1R expression constructs, we demonstrate that these novel mutations in *CSF1R* result in a loss-of-function protein being produced, which is actively targeted for degradation by the UPS. Upon examination of peripheral blood mononuclear cell (PBMC) populations of these ALSP patients, we detected a reduction in differentiated PBMCs. Isolating and producing macrophages from ALSP donors revealed ALSP macrophages to have aberrant morphologies and reduced phagocytic capacity, revealing a deficit in peripheral macrophage function. Using mice heterozygous for *Csf1r*, we show that loss of *Csf1r* in bone-marrow-derived macrophages, but not microglia, negatively impacts phagocytosis. We subsequently show that loss of *Csf1r* in macrophages reduces the macrophage response to brain-derived amyloid- β . In addition to the reduced phagocytosis caused by *Csf1r* loss, this may produce a circulating macrophage population conducive to amyloid- β accumulation over life. Rather than forming senile plaques, this amyloid accumulation was exclusively observed in brain microvessels in ALSP patients. This is likely due to dysregulated BBB tight junction maintenance caused by the crosstalk between endothelial cells and microglia heterozygous for *Csf1r*.

Impact

As ALSP is widely considered to be a microgliopathy, therapeutic considerations have been focused on a target within the CNS. There have been recent successes with haematopoietic stem cell transplantation in the treatment of ALSP and other leucodystrophies; however, there is a critical lack of understanding as to how this treatment provides benefit. Here, we propose that restoration of the peripheral immune system facilitates the clearance of aggregates within the brain through replacement of circulating variant-CSF1R expressing macrophages, restoring differentiation, phagocytic capacity, macrophage localisation to regions of amyloid- β deposition. We identify the BBB as a potential hub of pathologic microglial–endothelial signalling which drives the cerebrovascular pathology of the disease and demonstrate in life breakdown of the BBB during early stages of the disease. Intriguingly, targeting systemic macrophages and BBB integrity could also show promise for multiple other neurodegenerative conditions, which currently have no approved therapies.

Acknowledgements

This work was supported by grants from Science Foundation Ireland (SFI), (12/Y1/B2614 and 11/P1/1080), The Irish Research Council (IRC), The Health Research Board of Ireland (HRB), the BrightFocus Foundation. The Campbell

lab at TCD is also supported by an SFI Centres grant supported in part by a research grant from SFI under grant number 16/RC/3948 and co-funded under the European Regional Development fund by FutureNeuro industry partners. The Campbell lab is also supported by a European Research Council (ERC) grant, “Retina-Rhythm” (864522). SNS is supported as a senior principal investigator by the Flanders Institute for Biotechnology (VIB, Belgium). We would like to thank the VIB Biomedicine Core (Ghent, Belgium) for training, support and access to the instrument park. We thank Charles Murray for animal husbandry.

Author contributions

CD designed the study, performed experiments and wrote the manuscript. MF conducted neuropathological diagnosis and analysis. CD conducted human MRI studies. KB conducted FACS analysis. EOK conducted human MRI analysis. CG and KB conducted *in vitro* experiments. EK conducted human MRI studies. NB conducted neuropathological diagnosis and analysis. PH isolated bloods from patients. SC diagnosed patients. SS performed crystal structure modelling. SD designed the study and wrote the paper. MC designed the study and wrote the paper. All authors contributed to writing and have approved the final version of the manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.

For more information

- i <https://www.futureneurocentre.ie/>
- ii <https://www.tcd.ie/Genetics/research/campbell.php>

References

- Adams SJ, Kirk A, Auer RN (2018) Adult-onset leucoencephalopathy with axonal spheroids and pigmented glia (ALSP): Integrating the literature on hereditary diffuse leucoencephalopathy with spheroids (HDLS) and pigmentary orthochromatic leukodystrophy (POLD). *J Clin Neurosci* 48: 42–49
- Askw K, Li K, Olmos-Alonso A, Garcia-Moreno F, Liang Y, Richardson P, Tipton T, Chapman MA, Riecken K, Beccari S et al (2017) Coupled proliferation and apoptosis maintain the rapid turnover of microglia in the adult brain. *Cell Rep* 18: 391–405
- Axelsson R, Roytta M, Sourander P, Akesson HO, Andersen O (1984) Hereditary diffuse leucoencephalopathy with spheroids. *Acta Psychiatr Scand Suppl* 314: 1–65
- Van Bogaert LNR (1936) Le type tardif de la leukodystrophie progressive familiale. *Rev Neurol* 65: 21–45
- Bohlen CJ, Bennett FC, Tucker AF, Collins HY, Mulinyawe SB, Barres BA (2017) Diverse requirements for microglial survival, specification, and function revealed by defined-medium cultures. *Neuron* 94: 759–773.e8
- Cox DJ, Field RH, Williams DG, Baran M, Bowie AG, Cunningham C, Dunne A (2015) DNA sensors are expressed in astrocytes and microglia *in vitro* and are upregulated during gliosis in neurodegenerative disease. *Glia* 63: 812–825
- Dagher NN, Najafi AR, Kayala KMN, Elmore MRP, White TE, Medeiros R, West BL, Green KN (2015) Colony-stimulating factor 1 receptor inhibition prevents microglial plaque association and improves cognition in 3xTg-AD mice. *J Neuroinflammation* 12: 139
- Dai XM, Ryan GR, Hapel AJ, Dominguez MG, Russell RG, Kapp S, Sylvestre V, Stanley ER (2002) Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte

- deficiency, increased primitive progenitor cell frequencies, and reproductive defects. *Blood* 99: 111–120
- Durham BH, Lopez Rodrigo E, Picarsic J, Abramson D, Rotemberg V, De Munck S, Pannecoucke E, Lu SX, Pastore A, Yoshimi A *et al* (2019) Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. *Nat Med* 25: 1839–1842
- Elegheert J, Desfosses A, Shkumatov AV, Wu X, Bracke N, Verstraete K, Van Craenenbroeck K, Brooks BR, Svergun DI, Vergauwen B *et al* (2011) Extracellular complexes of the hematopoietic human and mouse CSF-1 receptor are driven by common assembly principles. *Structure* 19: 1762–1772
- Elmore MRP, Hohsfield LA, Kramár EA, Soreq L, Lee RJ, Pham ST, Najafi AR, Spangenberg EE, Wood MA, West BL *et al* (2018) Replacement of microglia in the aged brain reverses cognitive, synaptic, and neuronal deficits in mice. *Aging Cell* 17: e12832
- Felix J, Elegheert J, Gutsche I, Shkumatov AV, Wen Y, Bracke N, Pannecoucke E, Vandenberghe I, Devreese B, Svergun DI *et al* (2013) Human IL-34 and CSF-1 establish structurally similar extracellular assemblies with their common hematopoietic receptor. *Structure* 21: 528–539
- Felix J, De Munck S, Verstraete K, Meuris L, Callewaert N, Elegheert J, Savvides SN (2015) Structure and assembly mechanism of the signaling complex mediated by human CSF-1. *Structure* 23: 1621–1631
- Gelfand JM, Greenfield AL, Barkovich M, Mendelsohn BA, Van Haren K, Hess CP, Mannis GN (2020) Allogeneic HSCT for adult-onset leukoencephalopathy with spheroids and pigmented glia. *Brain* 143: 503–511
- Hawkes CA, McLaurin J (2009) Selective targeting of perivascular macrophages for clearance of β -amyloid in cerebral amyloid angiopathy. *Proc Natl Acad Sci USA* 106: 1261–1266
- Jin S, Sonobe Y, Kawanokuchi J, Horiuchi H, Cheng Y, Wang Y, Mizuno T, Takeuchi H, Suzumura A (2014) Interleukin-34 restores blood-brain barrier integrity by upregulating tight junction proteins in endothelial cells. *PLoS One* 9: 1–11
- Kemphorne L, Yoon H, Madore C, Smith S, Wszolek ZK, Rademakers R, Kim J, Butovsky O, Dickson DW (2020) Loss of homeostatic microglial phenotype in CSF1R-related leukoencephalopathy. *Acta Neuropathol Commun* 8: 72
- Kinnecom C, Lev MH, Wendell L, Smith EE, Rosand J, Frosch MP, Greenberg SM (2007) Course of cerebral amyloid angiopathy-related inflammation. *Neurology* 68: 1411–1416
- Laske C, Stransky E, Hoffmann N, Maetzler W, Straten G, Eschweiler GW, Leyhe T (2010) Macrophage colony-stimulating factor (M-CSF) in plasma and CSF of patients with mild cognitive impairment and Alzheimers disease. *Curr Alzheimer Res* 7: 409–414
- Liu YC, Tsai YH, Tang SC, Liou HC, Kang KH, Liou HH, Jeng JS, Fu WM (2018) Cytokine MIF enhances blood-brain barrier permeability: impact for therapy in ischemic stroke. *Sci Rep* 8: 1–12
- Luo J, Elwood F, Britschgi M, Villeda S, Zhang H, Ding Z, Zhu L, Alabsi H, Getachew R, Narasimhan R *et al* (2013) Colony-stimulating factor 1 receptor (CSF1R) signaling in injured neurons facilitates protection and survival. *J Exp Med* 210: 157–172
- Ma X, Lin WY, Chen Y, Stawicki S, Mukhyala K, Wu Y, Martin F, Bazan JF, Starovasnik MA (2012) Structural basis for the dual recognition of helical cytokines IL-34 and CSF-1 by CSF-1R. *Structure* 20: 676–687
- Matthews FE, Brayne C, Lowe J, McKeith I, Wharton SB, Ince P (2009) Epidemiological pathology of dementia: attributable-risks at death in the medical research council cognitive function and ageing study. *PLoS Medicine* 6: e1000180
- Michaud JP, Bellavance MA, Préfontaine P, Rivest S (2013) Real-time *in vivo* imaging reveals the ability of monocytes to clear vascular amyloid beta. *Cell Rep* 5: 646–653
- Mochel F, Delorme C, Czernecki V, Froger J, Cormier F, Ellie E, Fegueux N, Lehéricy S, Lumbroso S, Schiffmann R *et al* (2019) Haematopoietic stem cell transplantation in CSF1R-related adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. *J Neurol Neurosurg Psychiatry* 90: 1375–1376
- Nicholson AM, Baker MC, Finch NA, Rutherford NJ, Wider C, Graff-Radford NR, Nelson PT, Clark HB, Wszolek ZK, Dickson DW *et al* (2013) CSF1R mutations link POLD and HDLS as a single disease entity. *Neurology* 80: 1033–1040
- Rademakers R, Baker M, Nicholson AM, Rutherford NJ, Finch N, Soto-Ortolaza A, Lash J, Wider C, Wojtas A, DeJesus-Hernandez M *et al* (2011) Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. *Nat Genet* 44: 200–205
- Renee M, Elmore P, Najafi AR, Koike MA, Nazih N, Spangenberg EE, Rice RA, Kitazawa M, Nguyen H, West BL *et al* (2015) CSF1 receptor signaling is necessary for microglia viability, which unmasks a cell that rapidly repopulates the microglia-depleted adult brain. *Neuron* 82: 380–397
- Rice RA, Spangenberg EE, Yamate-Morgan H, Lee RJ, Arora RPS, Hernandez MX, Tenner AJ, West BL, Green KN (2015) Elimination of microglia improves functional outcomes following extensive neuronal loss in the hippocampus. *J Neurosci* 35: 9977–9989
- Rojo R, Raper A, Ozdemir DD, Lefevre L, Grabert K, Wollscheid-Lengeling E, Bradford B, Caruso M, Gazova I, Sánchez A *et al* (2019) Deletion of a Csf1r enhancer selectively impacts CSF1R expression and development of tissue macrophage populations. *Nat Commun* 10: 1–17
- Schwarzer P, Kokona D, Ebnetter A, Zinkernagel MS, Tidball AM, Dang LT, Glenn TW, Kilbane EG, Klarr DJ, Margolis JL *et al* (2019) Interleukin-34 selectively enhances the neuroprotective effects of microglia to attenuate oligomeric amyloid- β neurotoxicity. *Nat Commun* 10: 1–12
- Singh AB, Uppada SB, Dhawan P (2017) Claudin proteins, outside-in signaling, and carcinogenesis. *Pflügers Archiv* 469: 69–75
- Spangenberg E, Severson PL, Hohsfield LA, Crapser J, Zhang J, Burton EA, Zhang Y, Spevak W, Lin J, Phan NY *et al* (2019) Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer's disease model. *Nat Commun* 10: 1–21
- Spangenberg EE, Lee RJ, Najafi AR, Rice RA, Elmore MRP, Blurton-Jones M, West BL, Green KN (2016) Eliminating microglia in Alzheimer's mice prevents neuronal loss without modulating amyloid- β pathology. *Brain* 139: 1265–1281
- Srivastava PK, van Eyll J, Godard P, Mazzuferi M, Delahaye-Duriez A, Van Steenwinkel J, Gressens P, Danis B, Vandenplas C, Foerch P *et al* (2018) A systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug target. *Nat Commun* 9: 3561
- Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A *et al* (2015) Tissue-based map of the human proteome. *Science* 347: 1260419
- Vukic V, Callaghan D, Walker D, Lue LF, Liu QY, Couraud PO, Romero IA, Weksler B, Stanimirovic DB, Zhang W (2009) Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway. *Neurobiol Dis* 34: 95–106

- Walter M, Lucet IS, Patel O, Broughton SE, Bamert R, Williams NK, Fantino E, Wilks AF, Rossjohn J (2007) The 2.7 Å Crystal structure of the autoinhibited human c-Fms kinase domain. *J Mol Biol* 367: 839–847
- Wang Y, Szretter KJ, Vermi W, Gilfillan S, Rossini C, Cella M, Barrow AD, Diamond MS, Colonna M (2012) IL-34 is a tissue-restricted ligand of CSF1R required for the development of langerhans cells and microglia. *Nat Immunol* 13: 753–760
- Wu S, Xue R, Hassan S, Nguyen TML, Wang T, Pan H, Xu J, Liu Q, Zhang W, Wen Z (2018) Il34-Csf1r pathway regulates the migration and colonization of microglial precursors. *Dev Cell* 46: 552–563.e4
- Yona S, Kim KW, Wolf Y, Mildner A, Varol D, Breker M, Strauss-Ayali D, Viukov S, Guilliams M, Misharin A et al (2013) Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. *Immunity* 38: 79–91
- Zhang S, Zhao J, Zhang Y, Zhang Y, Cai F, Wang L, Song W (2019) Upregulation of MIF as a defense mechanism and a biomarker of Alzheimer's disease. *Alzheimer's Res Ther* 11: 54
- Zhang Y, Gu R, Jia J, Hou T, Zheng LT, Zhen X (2016) Inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity suppresses microglia-mediated inflammatory responses. *Clin Exp Pharmacol Physiol* 43: 1134–1144



License: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.